Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies
British Journal of Anaesthesia · 2026-08 · 137 (2) · 440-449
DOI: 10.1016/j.bja.2026.05.004 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Anaesthesia, 2026-08. Verfasst von Fisnik Haziri und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Switzerland; GREAT Netwo…. Hauptthemen laut MEDLINE: Postoperative Complications, Sodium-Glucose Transporter 2 Inhibitors, Perioperative Care, Heart Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca AG, Boehringer Ingelheim GmbH, Swiss Heart Foundation.
Abstract (Originalsprache)
BACKGROUND: International clinical practice guidelines recommend discontinuing sodium-glucose cotransporter-2 inhibitors (SGLT2i) 3-4 days before surgery to prevent euglycemic diabetic ketoacidosis, chiefly on the basis of case reports/series. Whether SGLT2i discontinuation may increase the risk of postoperative cardiovascular complications is unclear. METHODS: In a secondary analysis of the Basel-PMI (NCT02573532) and PMI-Vital (NCT05866874) prospective cohort studies in major noncardiac surgery, the exposure of interest was continuing, or stopping, SGLT2i in participants receiving chronic SGLT2i therapy. The primary outcome was an ordinal composite of acute heart failure hospitalisation and cardiovascular death within 90 days of surgery, adjusting for prespecified covariates. Secondary outcomes included the incidence of euglycemic diabetic ketoacidosis within 7 days. RESULTS: Among 451 study participants receiving SGLT2i (mean age 72 (range: 47-86) yr; 22% women), 404/451 (89.6%) had diabetes mellitus, and 166/451 (36.9%) had chronic heart failure. SGLT2i were discontinued before surgery in 393/451 (87.1%) participants (39.2% for 1 day, 34.4% for 2 days, 13.5% for ≥3 days). Cardiovascular complications occurred in 1/58 (1.7%) participants who continued SGLT2i, compared with 10/177 (5.7%) stopping for 1 day, 13/155 (8.4%) stopping for 2 days and 7/61 (11.5%) stopping for ≥3 days (P=0.011; adjusted odds ratio: 1.58 [95% confidence interval: 1.08-2.30] per discontinued day). Euglycemic diabetic ketoacidosis occurred in 1/451 participants after SGLT2i discontinuation. CONCLUSIONS: Perioperative SGLT2i discontinuation was associated with a substantially increased risk of 90-day cardiac complications. This suggests potential harm in current guideline recommendations; randomised controlled trials are needed to confirm these findings. STUDY REGISTRATION: NCT02573532, NCT05866874.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Switzerland; GREAT Network, Rome, Italy.
- Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Switzerland; GREAT Network, Rome, Italy. Electronic address: koray.durak@usb.ch.
- Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Switzerland; Department of Anaesthesia, University Hospital Basel, University of Basel, Switze…
- Department of Anaesthesia, University Hospital Basel, University of Basel, Switzerland.
- Department of Anaesthesia, University Hospital Basel, University of Basel, Switzerland; Department of Clinical Research, University of Basel, Switzerland.
- Department of Vascular Surgery, University Hospital Basel, University of Basel, Switzerland.
Förderung
- AstraZeneca AG
- Boehringer Ingelheim GmbH
- Swiss Heart Foundation
- F. Hoffmann-La Roche Ltd
- Novo Nordisk A/S
- Abbott Fund
- University Hospital Basel
- Swiss National Science Foundation
Zitieren
APA
Haziri, F., Durak, K., Glarner, N., Ergin, E., Burri-Winkler, K., Kaplan, E., Thommen, V., Pargger, M., Huré, G., Giger, R. V., Bolliger, D., Steiner, L. A., Mujagic, E., Lardinois, D., Schären, S., Mueller, A., Kunz, M., Stolte, T., Mahfoud, F., …, & Mueller, C. (2026). Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies. British Journal of Anaesthesia, 137(2), 440-449. https://doi.org/10.1016/j.bja.2026.05.004
Vancouver
Haziri F, Durak K, Glarner N, Ergin E, Burri-Winkler K, Kaplan E, et al. Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies. British Journal of Anaesthesia. 2026;137(2):440-449. doi:10.1016/j.bja.2026.05.004
BibTeX
@article{Haziri2026,
author = {Haziri, Fisnik and Durak, Koray and Glarner, Noemi and Ergin, Emre and Burri-Winkler, Katrin and Kaplan, Emel and Thommen, Vanessa and Pargger, Mirjam and Huré, Gabrielle and Giger, Rafael V and Bolliger, Daniel and Steiner, Luzius A and Mujagic, Edin and Lardinois, Didier and Schären, Stefan and Mueller, Andreas and Kunz, Michael and Stolte, Thorald and Mahfoud, Felix and Strebel, Ivo and Puelacher, Christian and Gualandro, Danielle M and Mueller, Christian},
title = {Perioperative discontinuation of SGLT2-inhibitors and cardiac complications after noncardiac surgery: secondary analysis of two prospective observational cohort studies},
journal = {British Journal of Anaesthesia},
year = {2026},
volume = {137},
number = {2},
pages = {440--449},
doi = {10.1016/j.bja.2026.05.004}
}
EUVIMED